EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSPSIG00000016450
Gene Symbol: MAP3K5
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSPSIG00000015241
Gene Symbol: MAP3K8
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSPSIG00000015550
Gene Symbol: MAP3K9
2 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoamine Oxidase A

Ensembl ID : ENSPSIG00000015202
Gene Symbol: MAOA
4 Cross references
148 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Monoglyceride Lipase

Ensembl ID : ENSPSIG00000012935
Gene Symbol: MGLL
4 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Motilin Receptor

Ensembl ID : ENSPSIG00000002189
Gene Symbol: MLNR
1 Cross references
157 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mucosal Pentraxin-Like

Ensembl ID : ENSPSIG00000005361
Gene Symbol: LOC102457250
2 Cross references
442 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mucosal Pentraxin-Like

Ensembl ID : ENSPSIG00000005410
Gene Symbol: LOC102457504
2 Cross references
442 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 3

Ensembl ID : ENSPSIG00000005599
Gene Symbol: NPR3
4 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuronal Acetylcholine Receptor Subunit Alpha-7

Ensembl ID : ENSPSIG00000010525
Gene Symbol: LOC102454210
2 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y2

Ensembl ID : ENSPSIG00000000146
Gene Symbol: NPY2R
2 Cross references
246 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y5

Ensembl ID : ENSPSIG00000000800
Gene Symbol: NPY5R
4 Cross references
135 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).